35 results about "Yellow Fever Virus Infection" patented technology

The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.

The invention belongs to the technical field of biomedicines and in particular to a small molecular drug capable of inhibiting infection of Zika virus, dengue virus and / or yellow fever virus and an application thereof. In particular, the invention relates to a method of inhibiting infection of Zika virus, dengue virus and / or yellow fever virus by Montelukast sodium and an application of Montelukast sodium in preparing a drug for preventing and / or treating related symptoms or diseases of infection of Zika virus, dengue virus and / or yellow fever virus.

The invention discloses application of carbamazepine to preparation of medicines for treating flavivirus infection, particularly application of the carbamazepine to preparation of a medicine for treating Japanese b encephalitis virus infection, a medicine for treating Zika virus infection, a medicine for treating West Nile virus infection, a medicine for treating yellow fever virus infection and amedicine for treating 1-4 type dengue virus infection. The carbamazepine can effectively reduce the death rate of mice infected with Japanese b encephalitis virus; in addition, the carbamazepine hasbeen applied clinically for a long time and has high safety. Therefore, the carbamazepine can be further developed to serve as a medicine for treating flavivirus infection and provide new choice for clinical medication.

The invention relates to the technical field of biology and discloses a DNA molecule, a recombinant virus and a preparation method and application of the DNA molecule and the recombinant virus. The DNA molecule contains a 5' noncoding region sequence, a capsid protein coding sequence, a DNA sequence, a membrane protein precursor coding sequence, an envelope protein coding sequence, a non-structural protein coding sequence and a 3' noncoding region sequence, wherein the DNA sequence corresponds to an internal ribosome entry site sequence with the 5' end connected with a termination codon sequence, and all the sequences except the DNA sequence are derived from yellow fever virus attenuated strains. The cDNA sequence corresponding to the genome RNA of the recombinant virus is identical with the sequence of the DNA molecule. The DNA molecule can be used for building the recombinant virus so as to obtain a vaccine capable of effectively preventing yellow fever virus infection.

The invention discloses application of Lycojaponicumin A in preparation of a drug for treating or preventing yellow fever virus infection. The Lycojaponicumin A can effectively inhabit yellow fever virus proliferation, but has low cytotoxicity, can be further developed for the preparation of drugs for treating diseases caused by yellow fever virus infection and has wide application prospect. The application of the Lycojaponicumin A in the preparation of the drug for treating the yellow fever virus infection is disclosed for the first time. Due to the fact that the skeleton type is a novel skeleton type and the high yellow fever virus inhibiting activity of the Lycojaponicumin A is unexpectedly strong, the possibility that other compounds give any revelation does not exist, and the Lycojaponicumin A has outstanding substantive characteristics and meanwhile has a remarkable improvement in prevention and treatment of the yellow fever virus infection obviously.

The invention discloses a medicine composition containing carbamazepine and biotin and application thereof, and concretely relates to application of the medicine composition containing the biotin andthe carbamazepine in preparing Japanese B encephalitis virus infection medicines, zika virus infection medicines, west nile virus infection medicines, yellow fever virus infection medicines and 1-4 type dengue virus infection medicines. According to the medicine composition provided by the invention, the death rate of rats infected by Japanese B encephalitis virus can be effectively reduced; in addition, the biotin is vitamin necessary for a human body, and the carbamazepine is applied clinically for a long time and has favorable safety, so that the medicine composition containing the biotin and the carbamazepine can be further developed to be a medicine for treating flavivirus infection, and provides a new choice for clinical medication.

The invention discloses an application of Lycojaponicumin C in the preparation of medicines for treating or preventing yellow fever virus infection. The Lycojaponicumin C can be used for effectively inhibiting the proliferation of yellow fever virus, has very low toxicity on cells, can be further developed into the medicines for treating diseases caused by the virus infection and has wide application prospects. The application of the Lycojaponicumin C in the preparation of medicines for treating the yellow fever virus infection is disclosed for the first time. As the skeleton type of the Lycojaponicumin C belongs to a brand-new skeleton type, the Lycojaponicumin C has unexpected strong inhibitory activity on yellow fever virus, and the possibility that other compounds provide revelation does not exist. The Lycojaponicumin C has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for preventing or treating the yellow fever virus infection.

The invention discloses application of Gypensapogenin A to preparing drugs for treating or preventing yellow fever virus infection. Gypensapogenin A is capable of effectively inhibiting the proliferation of yellow fever virus, has little toxicity to cells, can be further developed as the drugs for treating diseases caused by virus infection and has extensive application prospect. The application of Gypensapogenin A to preparing the drugs for treating the yellow fever virus infection, disclosed by the invention, is firstly published, the framework type is brand new, the activity of inhibiting the yellow fever virus is unexpectedly strong and the probability of giving any revelation by other compounds does not exist, so that prominent substantive features are provided and a remarkable progress in preventing and treating the yellow fever virus infection is made at the same time.

The invention relates to pharmaceutical application of Cordyceps sinensis and provides application of Cordyceps sinensis in the preparation of drugs for preventing and / or treating yellow fever virus infections; the drugs include Cordyceps sinensis as an active ingredient and one or more pharmaceutically acceptable excipients, the Cordyceps sinensis is selected from natural Cordyceps sinensis, fermented Cordyceps sinensis mycelia and extract of the natural Cordyceps sinensis and fermented Cordyceps sinensis mycelia, and the extract is one, or a combination of any, of aqueous extract, alcohol extract, ester extract, ether extract and chloroform extract. Inhibition experiments on yellow fever virus prove that Cordyceps sinensis has good inhibition effect, and therefore it is proved that Cordyceps sinensis may be used to prevent and / or treat yellow fever virus infections and has the advantages such as significant effect, low side effect and high acting speed. Therefore, Cordyceps sinensis can be used to develop drugs for treating diseases due to yellow fever virus and has great social benefit and research value.

The invention discloses a highly functional and active yellow fever virus human monoclonal antibody and an application thereof, belonging to the technical field of medicine. In the present invention, the yellow fever virus E protein expressed by Escherichia coli is used as the antigen, and memory B cells that can specifically bind to the yellow fever virus E protein are screened from the PBMCs of a convalescent patient through flow sorting, and then the single B cells screened are screened. The cells are subjected to RT-PCR and PCR amplification to obtain variable region fragments of the antibody, which are further linked with the constant region into an expression vector. After being expressed and purified in mammalian cells, a series of functional tests were carried out to obtain a human monoclonal antibody capable of protecting against yellow fever virus infection. The antibody and antigen affinity is 0.588nM, has strong neutralizing yellow fever virus activity, IC50 is 3.7ng / ml, can completely protect mice from lethal dose of yellow fever virus attack, with clinical treatment and prevention of yellow fever virus Application value of heat virus.